Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume Increase – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw unusually-strong trading volume on Tuesday . Approximately 7,701 shares were traded during trading, an increase of 143% from the previous session’s volume of 3,172 shares.The stock last traded at $21.2950 and had previously closed at $21.50.

Analyst Ratings Changes

AAPG has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft began coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They issued a “buy” rating and a $40.00 price target for the company. Rodman & Renshaw initiated coverage on shares of Ascentage Pharma Group International in a research report on Tuesday, January 13th. They set a “buy” rating and a $48.00 target price on the stock. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Finally, BTIG Research reissued a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Monday, April 13th. Two investment analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, Ascentage Pharma Group International presently has a consensus rating of “Buy” and an average price target of $46.67.

Ascentage Pharma Group International Stock Performance

The firm’s fifty day simple moving average is $24.01 and its 200 day simple moving average is $27.03. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The firm had revenue of $24.72 million during the quarter. Sell-side analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current year.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several institutional investors have recently made changes to their positions in AAPG. Hsbc Holdings PLC acquired a new position in Ascentage Pharma Group International in the 2nd quarter worth about $391,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Ascentage Pharma Group International in the third quarter valued at approximately $96,000. ABC Arbitrage SA purchased a new position in Ascentage Pharma Group International during the third quarter worth approximately $204,000. UBS Group AG boosted its stake in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares during the last quarter. Finally, XY Capital Ltd grew its holdings in Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after buying an additional 12,530 shares in the last quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.